作者更正:Povorcitinib 治疗化脓性汗腺炎的 STOP-HS1 和 STOP-HS2 III 期随机双盲安慰剂对照试验
Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Nature Medicine 发布更正,修正 Povorcitinib 治疗化脓性汗腺炎 STOP-HS1 和 STOP-HS2 III 期临床试验论文中的数据错误。主要涉及患者基线疾病持续时间范围、STOP-HS2 试验停药人数及原因、P 值上标、生存曲线颜色及 Supplementary Table 6A 的数据列顺序。
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04534-z, published online 23 July 2026.
In the version of the article initially published, in the second paragraph of the “Patients” section of the Results, “Baseline disease characteristics were indicative of recalcitrant, longstanding HS (mean (range) disease duration, 9.7 (0.4−49.1)−10.8 (0.3−48.7) years)” should have read “Baseline disease characteristics were indicative of recalcitrant, longstanding HS (mean (range) disease duration, 9.7 (0.4−49.1)−10.8 (0.4−57.7) years)”. In the Fig. 1 legend, in footnote b, “In STOP-HS2, two patients discontinued after completing treatment through week 12: one discontinued due to physician decision, and one withdrew” should have read “In STOP-HS2, three patients discontinued after completing treatment through week 12: two discontinued due to physician decision, and one withdrew”; and footnote d was “Two patients discontinued after completing treatment through week 12; both withdrew” but should have been “One patient withdrew after completing treatment through week 12”. In Table 2, the superscript for the P values in STOP-HS1 for the 75 mg dose in the rows for ≥3-point decrease in Skin Pain NRS and Skin Pain NRS30 should be “f” rather than “e”. In Extended Data Fig. 5e, f, the grey dotted line between weeks 18 and 24 should have been blue and the values next to the week 6 dots should have been next to the week 12 dots. Additionally, in Supplementary Table 6A, the “Week 12” row of the “A75, Baseline A count, 3−5” section originally read “37.2 (16/43), 36.8 (25/68), 35.3 (18/51)” but should have read “36.8 (25/68), 35.3 (18/51), 37.2 (16/43)”. These corrections have been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Department of Dermatology, Harvard Medical School, Boston, MA, USA
Martina L. Porter
Beth Israel Deaconess Medical Center, Boston, MA, USA
Martina L. Porter
Inflammatory Diseases Unit, Department of Dermatology, Venereology and Surgery, Hospital de Manises, Valencia, Spain
Antonio Martorell
Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Christopher J. Sayed
ICH – International Center for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany
Falk G. Bechara
Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA
Hadar Lev-Tov
Department of Dermatology, University of Southern California, Los Angeles, CA, USA
Jennifer L. Hsiao
Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia
John W. Frew
Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia
John W. Frew
School of Clinical Medicine, University of New South Wales Sydney, Kensington, New South Wales, Australia
John W. Frew
Department of Dermatology, Polyclinique Courlancy-Bezannes, Reims-Bezannes, France
Ziad Reguiaï
Probity Medical Research, Waterloo, Ontario, Canada
Melinda J. Gooderham
SKiN Centre for Dermatology, Peterborough, Ontario, Canada
Melinda J. Gooderham
Queen’s University, Kingston, Ontario, Canada
Melinda J. Gooderham
Departments of Dermatology and Medicine, University of Minnesota, Minneapolis, MN, USA
Noah Goldfarb
Department of Dermatology, University of Minnesota Physicians, Minneapolis, MN, USA
Noah Goldfarb
Department of Dermatology, Erasmus Medical Center, Rotterdam, Netherlands
Hessel H. van der Zee
Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Veronique del Marmol
Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Angelo V. Marzano
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
Angelo V. Marzano
Oregon Medical Research Center, Portland, OR, USA
Benjamin D. Ehst
USA Medical Dermatology Specialists, US Dermatology Partners, Phoenix, AZ, USA
Lindsay S. Ackerman
Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Itabashi City, Tokyo, Japan
Koremasa Hayama
Incyte Corporation, Wilmington, DE, USA
Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown & Leandro L. Santos
Department of Dermatology, Venereology, and Immunology, Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany
Christos C. Zouboulis
Authors
- Martina L. Porter
- Antonio Martorell
- Christopher J. Sayed
- Falk G. Bechara
- Hadar Lev-Tov
- Jennifer L. Hsiao
- John W. Frew
- Ziad Reguiaï
- Melinda J. Gooderham
- Noah Goldfarb
- Hessel H. van der Zee
- Veronique del Marmol
- Angelo V. Marzano
- Benjamin D. Ehst
- Lindsay S. Ackerman
- Koremasa Hayama
- Chenwei Tian
- Jennifer Kelley
- Huiling Zhen
- Joslyn S. Kirby
- Kurt Brown
- Leandro L. Santos
- Christos C. Zouboulis
Corresponding author
Correspondence to Christos C. Zouboulis.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Porter, M.L., Martorell, A., Sayed, C.J. et al. Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat Med (2026). https://doi.org/10.1038/s41591-026-04747-2
Published: 21 October 2026
Version of record: 21 October 2026
DOI: https://doi.org/10.1038/s41591-026-04747-2
来源:Nature Medicine · nature.com